Twist Bioscience registers Invenra-linked shares for resale, confirming an old deal

This is a registration step, not a new transaction. Twist is filing a prospectus supplement so Invenra-related shares can be resold under the Registration Rights Agreement dated February 11, 2026; the underlying stock purchase agreement was already signed on that date.

The filing adds no operating update, new consideration, or revised outlook. It contains no revenue, earnings, guidance, financing, or change to the previously announced strategic arrangement; the substance is limited to resale registration and the related legal opinion. 〔0〕

The market read is therefore neutral. Any dilution or potential resale overhang belongs to the February transaction rather than this August 19, 2026 filing. This is compliance and liquidity paperwork confirming an already known arrangement, not an incremental surprise to reset expectations.